Antiproliferative effect of Aurora kinase targeting in mesothelioma

Lung Cancer

Volumn 70, Issue 3, 2010, Pages 271-279

  Crispi, Stefania ^a   Fagliarone, Claudia ^b   Biroccio, Annamaria ^b   D'Angelo, Carmen ^b   Galati, Rossella ^b   Sacchi, Ada ^b   Vincenzi, Bruno ^d   Baldi, Alfonso ^c   Verdina, Alessandra ^b  

^a INSTITUTE OF GENETICS AND BIOPHYSICS ADRIANO BUZZATI TRAVERSO   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Aurora kinase; Inhibitor; Mesothelioma; Potential target; Related genes; ZM447439

Indexed keywords

AURORA A KINASE; AURORA B KINASE; HISTONE H3; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; SERINE;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER TISSUE; CLINICAL ARTICLE; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

BENZAMIDES; CELL LINE, TUMOR; CELL PROLIFERATION; COMPUTATIONAL BIOLOGY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HUMANS; MESOTHELIOMA; MICROARRAY ANALYSIS; PHOSPHORYLATION; PLEURAL NEOPLASMS; PROTEIN-SERINE-THREONINE KINASES; QUINAZOLINES;

EID: 78049364363     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2010.03.005     Document Type: Article

References (36)

1. Mossman B.T., Kamp D.W., Weitzman S.A. Mechanisms of carcinogenesis and clinical features of asbestos-associated cancers. Cancer Invest 1996, 14:466-480.
2. Curran D., Sahmoud T., Therasse P., van Meerbeeck J., Postmus P.E., Giaccone G. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol 1998, 16:145-152.
3. Weder W., Stahel R.A., Bernhard J., Bodis S., Vogt P., Ballabeni P., et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007, 18:1196-1202.
4. Carmena M., Earnshaw W.C. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 2003, 4:842-854.
5. Tang C.J., Lin C.Y., Tang T.K. Dynamic localization and functional implications of Aurora-C kinase during male mouse meiosis. Dev Biol 2006, 290:398-410.
6. Chieffi P., Cozzolino L., Kisslinger A., Libertini S., Staibano S., Mansueto G., et al. Aurora B expression directly correlates with prostate cancer malignancy and influence prostate cell proliferation. Prostate 2006, 66:326-333.
7. Ewart-Toland A., Dai Q., Gao Y.T., Nagase H., Dunlop M.G., Farrington S.M., et al. Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis 2005, 26:1368-1373.
8. Li D., Zhu J., Firozi P.F., Abbruzzese J.L., Evans D.B., Cleary K., Friess H., et al. Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer. Clin Cancer Res 2003, 9:991-997.
9. Tchatchou S., Wirtenberger M., Hemminki K., Sutter C., Meindl A., Wappenschmidt B., et al. Aurora kinases A and B and familial breast cancer risk. Cancer Lett 2007, 247:266-272.
10. Ulisse S., Delcros J.G., Baldini E., Toller M., Curcio F., Giacomelli L., et al. Expression of Aurora kinases in human thyroid carcinoma cell lines and tissues. Int J Cancer 2006, 119:275-282.
11. Reiter R., Gais P., Jutting U., Steuer-Vogt M.K., Pickhard A., Bink K., et al. Aurora kinase a messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma. Clin Cancer Res 2006, 12:5136-5141.
12. Garuti L., Roberti M., Bottegoni G. Small molecule aurora kinase inhibitors. Curr Med Chem 2009, 16:1949-1963.
13. Cheung C.H., Coumar M.S., Hsieh H.P., Chang J.Y. Aurora kinase inhibitors in preclinical and clinical testing. Expert Opin Investig Drugs 2009, 18:379-398.
14. Lopez-Rios F., Chuai S., Flores R., Shimizu S., Ohno T., Wakahara K., et al. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res 2006, 66:2970-2979.
15. Kim K.W., Mutter R.W., Willey C.D., Subhawong T.K., Shinohara E.T., Albert J.M., et al. Inhibition of survivin and aurora B kinase sensitizes mesothelioma cells by enhancing mitotic arrests. Int J Radiat Oncol Biol Phys 2007, 67:1519-1525.
16. Crispi S., Calogero R.A., Santini M., Mellone P., Vincenzi B., Citro G., et al. Global gene expression profiling of human pleural mesotheliomas: identification of matrix metalloproteinase 14 (MMP-14) as potential tumour target. PLoS One 2009, 4(9):e7016.
17. Stoppoloni D., Cardillo I., Verdina A., Vincenzi B., Menegozzo S., Santini M., et al. Expression of the embryonic lethal abnormal vision-like protein HuR in human mesothelioma: association with cyclooxygenase-2 and prognosis. Cancer 2008, 113:2761-2769.
18. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
19. Peto R., Pike M.C., Armitage P., Breslow N.E., Cox D.R., Howard S.V., et al. Design and analysis of randomised clinical trials requiring prolonged observation of each patient. Br J Cancer 1977, 35:1-39.
20. O'Connor D.S., Grossman D., Plescia J., Li F., Zhang H., Villa A., Tognin S., et al. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc Natl Acad Sci USA 2000, 97:13103-13107.
21. Kufer T.A., Silljé H.H., Körner R., Gruss O.J., Meraldi P., Nigg E.A. Human TPX2 is required for targeting Aurora-A kinase to the spindle. J Cell Biol 2002, 158:617-623.
22. Hirota T., Kunitoku N., Sasayama T., Marumoto T., Zhang D., Nitta M., et al. Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 2003, 114:585-598.
23. Mapelli M., Massimiliano L., Santaguida S., Musacchio A. The Mad2 conformational dimer: structure and implications for the spindle assembly checkpoint. Cell 2007, 131:730-743.
24. Zhu C., Bossy-Wetzel E., Jiang W. Recruitment of MKLP1 to the spindle midzone/midbody by INCENP is essential for midbody formation and completion of cytokinesis in human cells. Biochem J 2005, 389:373-381.
25. Touré A., Mzali R., Liot C., Seguin L., Morin L., Crouin C., et al. Phosphoregulation of MgcRacGAP in mitosis involves Aurora B and Cdk1 protein kinases and the PP2A phosphatase. FEBS Lett 2008, 582:1182-1188.
26. Orthaus S., Biskup C., Hoffmann B., Hoischen C., Ohndorf S., Benndorf K., et al. Assembly of the inner kinetochore proteins CENP-A and CENP-B in living human cells. Chembiochem 2008, 9:77-92.
27. Qi M., Yu W., Liu S., Jia H., Tang L., Shen M., et al. Septin1, a new interaction partner for human serine/threonine kinase aurora-B. Biochem Biophys Res Commun 2005, 336:994-1000.
28. Wong J., Lerrigo R., Jang C.Y., Fang G., Aurora A regulates the activity of HURP by controlling the accessibility of its microtubule-binding domain. Mol Biol Cell 2008, 19:2083-2091.
29. Conte N., Delaval B., Ginestier C., Ferrand A., Isnardon D., Larroque C., et al. TACC1-chTOG-Aurora A protein complex in breast cancer. Oncogene 2003, 22:8102-8116.
30. Delaval B., Ferrand A., Conte N., Larroque C., Hernandez-Verdun D., Prigent C., et al. Aurora B-TACC1 protein complex in cytokinesis. Oncogene 2004, 23:4516-4522.
31. Wada N., Yoshida A., Miyagi Y., Yamamoto T., Nakayama H., Suganuma N., et al. Overexpression of the mitotic spindle assembly checkpoint genes hBUB1, hBUBR1 and hMAD2 in thyroid carcinomas with aggressive nature. Anticancer Res 2008, 28:139-144.
32. Scott M., Hyland P.L., McGregor G., Hillan K.J., Russell S.E., Hall P.A. Multimodality expression profiling shows SEPT9 to be overexpressed in a wide range of human tumours. Oncogene 2005, 24:4688-4700.
33. Lee E.C., Frolov A., Li R., Ayala G., Greenberg N.M. Targeting Aurora kinases for the treatment of prostate cancer. Cancer Res 2006, 66:4996-5002.
34. Ditchfield C., Johnson V.L., Tighe A., Ellston R., Haworth C., Johnson T., et al. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol 2003, 161:267-280.
35. Goto H., Yasui Y., Nigg E.A., Inagaki M. Aurora-B phosphorylates Histone H3 at serine28 with regard to the mitotic chromosome condensation. Genes Cells 2002, 7:11-17.
36. Girdler F., Gascoigne K.E., Eyers P.A., Hartmuth S., Crafter C., Foote K.M., et al. Validating Aurora B as an anti-cancer drug target. J Cell Sci 2006, 119:3664-3675.